Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focussing on Immune modulatory drugs

Objective

Until the age of biotechnology, treatment options for children and adolescents with severe arthritis, inflammatory bowel diseases and other serious diseases with chronic inflammation were limited. Advances in understanding the pathophysiology of the inflammatory responses have led to the development of a new class of medications that are capable of inhibiting selectively the principal mediators of inflammation and tissue damage. The introduction of these new immunomodulators, which are collectively termed biologics, has opened a new era in the treatment of inflammatory diseases. Recent reports however suggest unexpected increases in adverse - or serious events -associated with the use of these biologics. PHARMACHILD aims to detect, assess and understand long term and short term side effects of the use of biologics by studying the pharmacovigilance in a large international cohort of patients with Juvenile Idiopathic Arthritis (children and young adults) in order to support regulatory decisions on marketing authorizations for these products.

There is a clear need for a study that will enable the promotion of more effective and safer use of biologics in JIA as children and young adolescents represent an especially vulnerable patient group, JIA is the most common chronic disease of childhood treated with biologics, and data available from adults cannot be extrapolated to children. PHARMACHILD brings together leading European scientists in the field of infectious diseases, immunity, inflammation and oncology. Our network combines resources from international organizations and existing national registries. This combination will enable us to achieve the critical mass (in terms of expertise and resources) to identify the risk factors for developing adverse events, to elucidate the mechanisms involved in the adverse events (such as latent infection reactivation) and to develop methodologies for screening and predicting patients at risk.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Call for proposal

FP7-HEALTH-2010-single-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
EU contribution
€ 501 446,00
Address
HEIDELBERGLAAN 100
3584 CX Utrecht
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (8)